Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | IDH1 | O75874 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964800 | 0.88 | ALDH1A1 (0.61) | ARALDH1A1KDM4EUSP2IMPDH2 | |
| SCHEMBL393816 | 0.88 | ALDH1A1 (0.61) | ARALDH1A1KDM4EUSP2IMPDH2 | |
| SCHEMBL27439715 | 0.85 | AR (0.55) | ARALDH1A1KDM4EUSP2PGR | |
| SCHEMBL3971489 | 0.85 | AR (0.51) | ARALDH1A1KDM4EUSP2PGR | |
| SCHEMBL5112608 | 0.83 | POLB (0.49) | ARALDH1A1KDM4EUSP2IDH1 | |
| SCHEMBL21963833 | 0.83 | AR (0.74) | ARALDH1A1KDM4EUSP2PGR | |
| SCHEMBL21327476 | 0.83 | POLB (0.61) | ARALDH1A1KDM4EUSP2PGR | |
| SCHEMBL21327611 | 0.81 | AR (0.54) | ARALDH1A1KDM4EUSP2IMPDH2 | |
| SCHEMBL2761994 | 0.80 | ALDH1A1 (0.59) | ARALDH1A1KDM4EUSP2PGR | |
| SCHEMBL14661785 | 0.80 | PYCR1 (0.47) | ARALDH1A1KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094953-A | 1, 3-Dihydro-2H-pyrrolo [3,4-c ] quinoline derivatives as cGAS inhibitors for the treatment of inflammatory and/or autoimmune diseases | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026090589-A1 | HETEROCYCLIC HBS1L DEGRADERS | TANGO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4200015-B1 | SUBSTITUTED HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL MYERS SQUIBB CO (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4694889-A1 | COMPOUNDS AND METHODS FOR TREATING PROTEIN AGGREGATION DISEASES | Acelot, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4051680-B1 | CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-08-19 | — | — | US | disclosed |
| CN-114423758-B | Antibacterial compounds | 爱尔兰詹森科学公司 | 2025-05-27 | — | — | CN | disclosed |
| EP-4545516-A1 | PREPARATION OF A CHK1 INHIBITOR COMPOUND | Sentinel Oncology Limited (GB) | 2025-04-30 | — | — | EP | disclosed |
| EP-4347565-B1 | PREPARATION OF A CHK1 INHIBITOR COMPOUND | SENTINEL ONCOLOGY LTD (GB) | 2025-04-02 | — | — | EP | disclosed |
| CN-112812105-B | Aminopyridyloxy pyrazole derivative, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2025-04-01 | — | — | CN | disclosed |
| EP-1368318-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-12-10 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| US-20030212110-A1 | Glandular disorders; bone disorders | SMITHKLINE BEECHAM CORPORATION | 2003-11-13 | — | — | US | disclosed |
| WO-2003072561-A1 | BENZOFURAN AND BENZOTHIOPHENE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2002007673-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391697-B2 | Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase | ABL1, CDK1, CDK2 | AR 3751/4885ALDH1A1 2619/4885KDM4E 1308/4885 |
| US-20030212110-A1 | Glandular disorders; bone disorders | CYP24A1, PTH1R, SOST | AR 1779/4885ALDH1A1 3551/4885KDM4E 4705/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | AR 3317/4885ALDH1A1 99/4885KDM4E 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.